
Venus Concept VERO
Quarterly report 2025-Q3
added 05-16-2026
Venus Concept Gross Profit 2011-2026 | VERO
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Venus Concept
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 44.3 M | 52.2 M | 66 M | 74.1 M | 51.4 M | 76.7 M | 9.51 M | 9.15 M | 5.17 M | 4.72 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 76.7 M | 4.72 M | 39.3 M |
Quarterly Gross Profit Venus Concept
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.82 M | 9.43 M | 8.76 M | - | 9.92 M | 11.8 M | 11.6 M | - | 12.2 M | 14.2 M | 13.7 M | - | 13.4 M | 19 M | 17.8 M | - | 17.3 M | 18.7 M | 15.2 M | - | 13.5 M | 11.9 M | 9.28 M | - | 18.8 M | 20.1 M | 18.1 M | 2.57 M | 2.16 M | 2.96 M | 1.82 M | 2.76 M | 1.7 M | 2.3 M | 2.38 M | 2.01 M | 1.27 M | 1.1 M | 779 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.1 M | 779 K | 9.62 M |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
275 M | - | - | $ 3.31 B | ||
|
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
22.7 M | $ 11.16 | -0.09 % | $ 316 M | ||
|
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
532 M | $ 8.27 | 0.55 % | $ 1.24 B | ||
|
Aziyo Biologics
AZYO
|
6.6 M | - | 1.37 % | $ 20.5 M | ||
|
EDAP TMS S.A.
EDAP
|
26.6 M | $ 4.33 | 0.23 % | $ 162 M | ||
|
BioSig Technologies
BSGM
|
18 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
16.7 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | ||
|
LENSAR
LNSR
|
14.1 M | $ 5.86 | 1.03 % | $ 70.1 M | ||
|
Helius Medical Technologies
HSDT
|
5.52 M | $ 2.31 | 6.94 % | $ 50.9 M | ||
|
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | ||
|
Cytosorbents Corporation
CTSO
|
26.5 M | $ 0.47 | -0.53 % | $ 29.2 M | ||
|
OrthoPediatrics Corp.
KIDS
|
173 M | $ 18.4 | 0.93 % | $ 432 M | ||
|
LivaNova PLC
LIVN
|
940 M | $ 73.67 | 1.03 % | $ 4.02 B | ||
|
MiMedx Group
MDXG
|
346 M | $ 3.77 | 3.43 % | $ 557 M | ||
|
Delcath Systems
DCTH
|
73.4 M | $ 11.2 | 3.23 % | $ 401 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
19.2 M | $ 1.0 | -4.29 % | $ 16.9 M | ||
|
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
14.3 M | - | - | $ 10.2 M | ||
|
Pulmonx Corporation
LUNG
|
67.1 M | $ 1.54 | 14.55 % | $ 62.7 M | ||
|
Electromed
ELMD
|
50 M | $ 37.58 | -2.06 % | $ 318 M | ||
|
Myomo
MYO
|
26.9 M | $ 0.9 | 3.7 % | $ 37.7 M | ||
|
Butterfly Network
BFLY
|
45.7 M | $ 4.42 | 7.8 % | $ 1.09 B | ||
|
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M | ||
|
Orthofix Medical
OFIX
|
566 M | $ 12.16 | 0.58 % | $ 482 M | ||
|
GBS
GBS
|
1.25 M | - | -0.57 % | $ 7.12 M | ||
|
Sintx Technologies
SINT
|
461 K | $ 2.19 | -0.45 % | $ 6.07 M | ||
|
Profound Medical Corp.
PROF
|
11.4 M | $ 6.95 | 3.19 % | $ 210 M | ||
|
Globus Medical
GMED
|
1.02 B | $ 83.98 | 5.06 % | $ 11.4 B | ||
|
Insulet Corporation
PODD
|
1.94 B | $ 157.2 | 1.68 % | $ 11.1 B | ||
|
CONMED Corporation
CNMD
|
750 M | $ 36.7 | 1.44 % | $ 1.14 B | ||
|
Inspire Medical Systems
INSP
|
779 M | $ 44.19 | 3.87 % | $ 1.3 B | ||
|
TransMedics Group
TMDX
|
363 M | $ 68.79 | 4.01 % | $ 2.34 B | ||
|
Integer Holdings Corporation
ITGR
|
500 M | $ 91.17 | 0.81 % | $ 3.17 B | ||
|
Invacare Corporation
IVC
|
48.3 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
4.73 B | $ 82.96 | 0.97 % | $ 48.5 B |